Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 10/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 9/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625391 | 1.00 | S1PR1 (0.41) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL8625440 | 0.96 | FDFT1 (0.40) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL8625446 | 0.96 | FDFT1 (0.40) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL8624889 | 0.89 | EED (0.39) | S1PR1S1PR3 | |
| SCHEMBL8624891 | 0.89 | EED (0.39) | S1PR1S1PR3 | |
| SCHEMBL8624984 | 0.88 | EED (0.40) | — | |
| SCHEMBL8624983 | 0.88 | EED (0.40) | — | |
| SCHEMBL8619749 | 0.86 | ENPP2 (0.50) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL8619747 | 0.86 | ENPP2 (0.50) | S1PR1S1PR3S1PR4S1PR2ENPP2 | |
| SCHEMBL8619951 | 0.86 | PTPN1 (0.38) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |